Profile picture of Gonzalo Tapia Rico

Dr Gonzalo Tapia Rico

Profile picture of Gonzalo Tapia Rico

MBBS, PhD, FRACP

Medical Oncologist
Call
Enquire
Referrals
Adelaide (Kurralta Park)
08 8450 3375

Dr Gonzalo Tapia Rico is committed to achieving the best possible outcomes for his patients. He prides himself in building strong, lasting relationships with his patients and their loved ones, supporting them every step of the way.

Biography

Dr Gonzalo Tapia Rico is an experienced medical oncologist at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. He undertook medical training at the Complutense University of Madrid and completed medical oncology training at one of Spain’s most prestigious hospitals, Gregorio Marañón Hospital. In 2013 he received his PhD degree for research exploring alternative classifications of molecular subtypes in breast cancer.

Dr Tapia Rico subsequently worked as a medical oncologist in the United Kingdom at the Royal Infirmary and Western General Hospitals in Edinburgh and Addenbrooke’s Hospital in Cambridge. He moved to Australia in 2016. As medical oncology clinical research fellow at both The Queen Elizabeth Hospital and Royal Adelaide Hospital, he gained extensive knowledge and experience in all aspects of cancer clinical trials, with the overarching desire to make meaningful improvements to patient outcomes.

He maintains a strong interest in education, clinical trials and research in both his private practice and roles as Clinical Senior Lecturer at the University of Adelaide and Clinical Director of Education at Icon Cancer Centre Adelaide. He has published numerous peer-reviewed articles in leading publications such as Cancer Treatment Reviews and Critical Reviews in Oncology/Haematology. Dr Tapia Rico is a fellow of the Royal Australasian College of Physicians (FRACP) and a member of several leading Australian and international cancer research institutions.

Dr Tapia Rico speaks fluent English and Spanish, and looks forward to caring for patients and their loved ones in their preferred language. His clinical experience covers a broad range of solid tumour malignancies, with a special clinical interest in immunotherapy, melanoma, gastrointestinal cancer, lung cancer, thyroid cancer and breast cancer.

Publications

  • Immunotherapy in older patients with advanced melanoma: a review of current evidence. T. Foo, G. Tapia Rico & R. Roberts-Thomson. Drugs & Aging, 2020; 37, 411-423.

  • The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. G. Tapia Rico, M.M Chan & K.F Loo. Cancer Treat Rev, 2020 Jun; 86:102011.

  • The “pet effect” in cancer patients: risks and benefits of human-pet interaction. M.M. Chan & G Tapia Rico. Critical Reviews in Oncology/Haematology, 2019; 143, 56-61.

  • Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. G. Tapia-Rico & T.J. Price. Expert Opin Biol Ther, 2018 Apr; 18(4):449-457.

  • Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. G. Tapia Rico, M.Li, N. Pavlakis, C. Cehic & T.J. Price. Cancer Treat Rev. 2018 May;66:1-6.

Special Interests

Dr Gonzalo Tapia Rico accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Gastrointestinal cancer
  • Lung cancer
  • Melanoma

Languages spoken

  • English
  • Spanish

Affiliations & Memberships

  • Australasian Gastro-Intestinal Trials Group (AGITG)
  • European Society of Medical Oncology (ESMO)
  • Spanish Group of Breast Cancer Research (GEICAM)
  • Royal Australasian College of Physicians (RACP)
  • Spanish Society of Medical Oncology (SEOM)

Publications

  • Immunotherapy in older patients with advanced melanoma: a review of current evidence. T. Foo, G. Tapia Rico & R. Roberts-Thomson. Drugs & Aging, 2020; 37, 411-423.

  • The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. G. Tapia Rico, M.M Chan & K.F Loo. Cancer Treat Rev, 2020 Jun; 86:102011.

  • The “pet effect” in cancer patients: risks and benefits of human-pet interaction. M.M. Chan & G Tapia Rico. Critical Reviews in Oncology/Haematology, 2019; 143, 56-61.

  • Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. G. Tapia-Rico & T.J. Price. Expert Opin Biol Ther, 2018 Apr; 18(4):449-457.

  • Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. G. Tapia Rico, M.Li, N. Pavlakis, C. Cehic & T.J. Price. Cancer Treat Rev. 2018 May;66:1-6.

Search

Contact us
Become a patient